CIK 0001815776 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Revenue (USD) | 19.1 M | ||
| Net income (USD) | -82.1 M | -70.0 M | -101.1 M |
| Diluted EPS (USD/shares) | -2.85 | -35.71 | -1.84 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-09-08 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-11 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-11 | 8-K | 8-K items 2.02,9.01 | 2026-08-11 |
| 2026-07-02 | 8-K | 8-K items 5.02 | 2026-06-30 |
| 2026-06-26 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-06-15 | 4 | 4 | 2026-06-15 |
| 2026-06-15 | 4 | FORM 4 | 2026-06-15 |
| 2026-06-15 | 4 | FORM 4 | 2026-06-15 |
| 2026-06-15 | 4 | FORM 4 | 2026-06-15 |
| 2026-06-15 | 4 | FORM 4 | 2026-06-15 |
| 2026-06-15 | 4 | FORM 4 | 2026-06-15 |
| 2026-06-15 | 4 | FORM 4 | 2026-06-15 |
| 2026-06-12 | 8-K | 8-K items 5.07 | 2026-06-12 |
| 2026-05-11 | 10-Q | 10-Q | 2026-03-31 |
| 2026-05-11 | 8-K | 8-K items 2.02,9.01 | 2026-05-11 |
| 2026-04-28 | ARS | ARS | 2025-12-31 |
| 2026-04-28 | DEFA14A | DEFA14A | |
| 2026-04-28 | DEF 14A | DEF 14A | 2026-06-12 |
| 2026-04-27 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-04-08 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-03-30 | 4 | FORM 4 | 2026-03-27 |
| 2026-03-30 | 4 | FORM 4 | 2026-03-27 |
| 2026-03-30 | 4 | FORM 4 | 2026-03-27 |
| 2026-03-24 | S-8 | S-8 | |
| 2026-03-24 | 10-K | 10-K | 2025-12-31 |
Forms on file (last 1,000): 4 98, 8-K 57, 3 29, 10-Q 16, 424B3 14, CORRESP 14, UPLOAD 11, EFFECT 9. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=LENZ (0.002 USD), /gw/filings/filings?ticker=LENZ&form=8-K, /gw/filings/facts?ticker=LENZ&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange